Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Article

Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement

Marc A. Ellsworth, Malinda N. Harris, William A. Carey, Alan R. Spitzer and Reese H. Clark
Pediatrics April 2015, 135 (4) 643-648; DOI: https://doi.org/10.1542/peds.2014-3290
Marc A. Ellsworth
aDivision of Neonatal Medicine, Mayo Clinic, Rochester, Minnesota; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Malinda N. Harris
aDivision of Neonatal Medicine, Mayo Clinic, Rochester, Minnesota; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
William A. Carey
aDivision of Neonatal Medicine, Mayo Clinic, Rochester, Minnesota; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan R. Spitzer
bCenter for Research, Education and Quality, Pediatrix Medical Group, Sunrise, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reese H. Clark
bCenter for Research, Education and Quality, Pediatrix Medical Group, Sunrise, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Download PDF

Abstract

BACKGROUND: Inhaled nitric oxide (iNO) therapy is an off-label medication in infants <34 weeks’ gestational age. In 2011, the National Institutes of Health released a statement discouraging routine iNO use in premature infants. The objective of this study was to describe utilization patterns of iNO in American NICUs in the years surrounding the release of the National Institutes of Health statement. We hypothesized that iNO prescription rates in premature infants have remained unchanged since 2011.

METHODS: The Pediatrix Medical Group Clinical Data Warehouse was queried for the years 2009–2013 to describe first exposure iNO use among all admitted neonates stratified by gestational age.

RESULTS: Between 2009 and 2013, the rate of iNO utilization in 23- to 29-week neonates increased from 5.03% to 6.19%, a relative increase of 23% (confidence interval: 8%–40%; P = .003). Of all neonates who received iNO therapy in 2013, nearly half were <34 weeks’ gestation, with these infants accounting for more than half of all first exposure iNO days each year of the study period.

CONCLUSIONS: The rates of off-label iNO use in preterm infants continue to rise despite evidence revealing no clear benefit in this population. This pattern of iNO prescription is not benign and comes with economic consequences.

  • inhaled nitric oxide
  • neonate
  • prematurity
  • respiratory distress
  • Accepted January 16, 2015.
  • Copyright © 2015 by the American Academy of Pediatrics

Individual Login

Log in
You will be redirected to aap.org to login or to create your account.

Institutional Login

via Institution

You may be able to gain access using your login credentials for your institution. Contact your librarian or administrator if you do not have a username and password.

Log in through your institution

If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Pay Per Article - You may access this article (from the computer you are currently using) for 2 days for US$25.00

Regain Access - You can regain access to a recent Pay per Article purchase if your access period has not yet expired.

Offer Reprints

PreviousNext
Back to top

Advertising Disclaimer »

In this issue

Pediatrics
Vol. 135, Issue 4
1 Apr 2015
  • Table of Contents
  • Index by author
View this article with LENS
PreviousNext
Email Article

Thank you for your interest in spreading the word on American Academy of Pediatrics.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement
(Your Name) has sent you a message from American Academy of Pediatrics
(Your Name) thought you would like to see the American Academy of Pediatrics web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Request Permissions
Article Alerts
Log in
You will be redirected to aap.org to login or to create your account.
Or Sign In to Email Alerts with your Email Address
Citation Tools
Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement
Marc A. Ellsworth, Malinda N. Harris, William A. Carey, Alan R. Spitzer, Reese H. Clark
Pediatrics Apr 2015, 135 (4) 643-648; DOI: 10.1542/peds.2014-3290

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Off-Label Use of Inhaled Nitric Oxide After Release of NIH Consensus Statement
Marc A. Ellsworth, Malinda N. Harris, William A. Carey, Alan R. Spitzer, Reese H. Clark
Pediatrics Apr 2015, 135 (4) 643-648; DOI: 10.1542/peds.2014-3290
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Print
Download PDF
Insight Alerts
  • Table of Contents

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Conclusions
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • Comments

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Early Hypoxic Respiratory Failure in Extreme Prematurity: Mortality and Neurodevelopmental Outcomes
  • Inhaled Pulmonary Vasodilators in the Neonatal and Pediatric ICU
  • Outcomes of outborn extremely preterm neonates admitted to a NICU with respiratory distress
  • Inhaled Nitric Oxide for Preterm Infants: What Can Change Our Practice?
  • Inhaled Nitric Oxide in Extremely Premature Neonates With Respiratory Distress Syndrome
  • A Quality Improvement Project to Improve Evidence-Based Inhaled Nitric Oxide Use
  • Short-term and long-term outcomes of preterm neonates with acute severe pulmonary hypertension following rescue treatment with inhaled nitric oxide
  • Impact of Stewardship on Inhaled Nitric Oxide Utilization in a Neonatal ICU
  • Year in Review 2015: Neonatal Respiratory Care
  • Inhaled nitric oxide decreases pulmonary endothelial nitric oxide synthase expression and activity in normal newborn rat lungs
  • Inhaled Nitric Oxide for the Preterm Infant: Evidence Versus Practice
  • Google Scholar

More in this TOC Section

  • Neighborhood Child Opportunity Index and Adolescent Cardiometabolic Risk
  • Neonates Born to Mothers With COVID-19: Data From the Spanish Society of Neonatology Registry
  • Comparison of Manual and Automated Sepsis Screening Tools in a Pediatric Emergency Department
Show more Article

Similar Articles

Subjects

  • Fetus/Newborn Infant
    • Fetus/Newborn Infant
    • Neonatology

Keywords

  • inhaled nitric oxide
  • neonate
  • prematurity
  • respiratory distress
  • Journal Info
  • Editorial Board
  • Editorial Policies
  • Overview
  • Licensing Information
  • Authors/Reviewers
  • Author Guidelines
  • Submit My Manuscript
  • Open Access
  • Reviewer Guidelines
  • Librarians
  • Institutional Subscriptions
  • Usage Stats
  • Support
  • Contact Us
  • Subscribe
  • Resources
  • Media Kit
  • About
  • International Access
  • Terms of Use
  • Privacy Statement
  • FAQ
  • AAP.org
  • shopAAP
  • Follow American Academy of Pediatrics on Instagram
  • Visit American Academy of Pediatrics on Facebook
  • Follow American Academy of Pediatrics on Twitter
  • Follow American Academy of Pediatrics on Youtube
  • RSS
American Academy of Pediatrics

© 2021 American Academy of Pediatrics